Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Borget

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
BMC Cancer|December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyIsabelle Borget, Maurice Pérol, David Pérol, et al.
The New England Journal of Medicine|May 4, 2012
Strategies of radioiodine ablation in patients with low-risk thyroid cancerMartin Schlumberger, Bogdan Catargi, Isabelle Borget, et al.
Oral Oncology|November 21, 2016
Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-testHaïtham Mirghani, Odile Casiraghi, Joanne Guerlain, et al.
Therapie|December 4, 2022
Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?Gérard de Pouvourville, Xavier Armoiry, Aurélie Lavorel, et al.
Therapie|November 29, 2022
Gérard de Pouvourville, Xavier Armoiry, Aurélie Lavorel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL TrialIsabelle Borget, Julia Bonastre, Bogdan Catargi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
International Journal of Cancer|April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaJulien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
BMC Cancer|December 17, 2014
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyIsabelle Borget, Maurice Pérol, David Pérol, et al.
The New England Journal of Medicine|May 4, 2012
Strategies of radioiodine ablation in patients with low-risk thyroid cancerMartin Schlumberger, Bogdan Catargi, Isabelle Borget, et al.
Oral Oncology|November 21, 2016
Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-testHaïtham Mirghani, Odile Casiraghi, Joanne Guerlain, et al.
Therapie|December 4, 2022
Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?Gérard de Pouvourville, Xavier Armoiry, Aurélie Lavorel, et al.
Therapie|November 29, 2022
Gérard de Pouvourville, Xavier Armoiry, Aurélie Lavorel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL TrialIsabelle Borget, Julia Bonastre, Bogdan Catargi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Impact of COVID-19 on healthcare organisation and cancer outcomesAurelie Bardet, Alderic M Fraslin, Jamila Marghadi, et al.
International Journal of Cancer|April 23, 2014
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaJulien Hadoux, Judith Favier, Jean-Yves Scoazec, et al.
European Urology|November 18, 2021
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC TrialGiulia Baciarello, Remy Delva, Gwenaelle Gravis, et al.
Pageof 14